biostudies-literatureShen RClinical research project by Shanghai Jiao Tong University School of MedicineChang Jiang Scholars Program, Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant SupportNational Key R&D Program of ChinaClinical Research Plan of Shanghai Hospital Development CenterSamuel Waxman Cancer Research FoundationNational Natural Science Foundation of ChinaMunicipal Human Resources Development Program for Outstanding Young Talents in Medical and Health Sciences in ShanghaiTalent (Class A) of Guangci Excellence Youth PlanShanghai Rising-Star ProgramNational Key Research and Development Program of Chinae70310https://www.ebi.ac.uk/biostudies/studies/S-EPMC12017895biostudies-literatureUnknown15(4)<h4>Background</h4>CD19 chimeric antigen receptor (CAR) T-cell therapy is a potential treatment for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The combination of targeted therapeutic strategies, particularly bruton tyrosine kinase inhibitor zanubrutinib and programmed death-1 inhibitor tislelizumab, may improve clinical outcomes and modulate the tumour microenvironment (TME).<h4>Methods</h4>We studied patients with R/R LBCL who received response-adapted zanubrutinib plus tislelizumab upon CD19 CAR T-cell therapy between June 2021 and March 2023. Patients were treated with zanubrutinib daily from leukapheresis to day 28 post-infusion; those achieving complete response continued zanubrutinib monotherapy for 3 months, while partial responders received combined zanubrutinib for 3 Clinical and translational medicineResponse-adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T-cell therapy in relapsed/refractory large B-cell lymphoma: A retrospective observational study.PMC12017895KY2023727YW20220022GCQN-2019-A162022YFC250260082400222SHDC2022CRD033SHDC2020CR1032BCARTFR-05824002272015220619QA14560020152208821300042017YQ075Cao WGYi HMDong YWeng XQLiu MKZhao WLLi LXu PPWang LCheng SYan ZXZhang YLSong QShen RJiang XFWu WWang YChen SSheng LSfalseResponse-adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T-cell therapy in relapsed/refractory large B-cell lymphoma: A retrospective observational study.<h4>Background</h4>CD19 chimeric antigen receptor (CAR) T-cell therapy is a potential treatment for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The combination of targeted therapeutic strategies, particularly bruton tyrosine kinase inhibitor zanubrutinib and programmed death-1 inhibitor tislelizumab, may improve clinical outcomes and modulate the tumour microenvironment (TME).<h4>Methods</h4>We studied patients with R/R LBCL who received response-adapted zanubrutinib plus tislelizumab upon CD19 CAR T-cell therapy between June 2021 and March 2023. Patients were treated with zanubrutinib daily from leukapheresis to day 28 post-infusion; those achieving complete response continued zanubrutinib monotherapy for 3 months, while partial responders received combined zanubrutinib for 3 2025-01-01T00:00:00Z2025 Apr2026-06-01T21:08:37.748Z2026-05-22T03:07:51.667ZS-EPMC120178954026851610.1002/ctm2.70310